Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

PARP inhibitors and their side effects in solid tumour therapy

Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA
PARP inhibitors and their side effects in solid tumour therapy ( Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA )
8 May 2019

Benefits and challenges of using PARP inhibitors to treat metastatic breast cancer

Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA
Benefits and challenges of using PARP inhibitors to treat metastatic breast cancer ( Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA )
8 May 2019

A clinical nurse specialist led multidisciplinary approach to breast cancer survivorship

Colleen Zombek - Ohiohealth, Columbus, USA
A clinical nurse specialist led multidisciplinary approach to breast cancer survivorship ( Colleen Zombek - Ohiohealth, Columbus, USA )
8 May 2019

Providing safe care to hereditary cancer patients and families

Suzanne Mahon - Saint Louis University, Missouri, USA
Providing safe care to hereditary cancer patients and families ( Suzanne Mahon - Saint Louis University, Missouri, USA )
8 May 2019

Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC

Luciana Molinero - Genentech, San Francisco, USA
Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC ( Luciana Molinero - Genentech, San Francisco, USA )
18 Apr 2019

KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy

Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea
KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy ( Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea )
15 Apr 2019

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer

Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA
Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer ( Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA )
15 Apr 2019

Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer

Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA
Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer ( Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA )
15 Apr 2019

Trends in breast cancer incidence and risk

Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA
Trends in breast cancer incidence and risk ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )
15 Apr 2019

The epidemiological shift of cancer

Dr Antonella Brunello - Istituto Oncologico Veneto, Padova, Italy
The epidemiological shift of cancer ( Dr Antonella Brunello - Istituto Oncologico Veneto, Padova, Italy )
21 Mar 2019

Breast cancer trials and the ageing population

Dr Etienne Brain - Institut Curie, Paris, France
Breast cancer trials and the ageing population ( Dr Etienne Brain - Institut Curie, Paris, France )
21 Mar 2019

BGICC 2019

BGICC 2019 ( )
28 Jan 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation